SCHEMBL4025032

SCHEMBL4025032

Cc1ccccc1C1C(C(=O)c2ccccc2)CN(CC(=O)N(C)C)CC1C(=O)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.37
RORC P51449 1/20 0.37
USP2 O75604 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
HDAC4 P56524 1/20 0.35
KCNH2 Q12809 1/20 0.35
MAOB P27338 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
GRIN2B Q13224 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
DRD4 P21917 1/20 0.34
PROKR1 Q8TCW9 1/20 0.33
EP300 Q09472 1/20 0.33
CREBBP Q92793 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4025031 1.00 LMNA (0.37) LMNARORCUSP2ALDH1A1MAPT
SCHEMBL4020344 0.92 KIF11 (0.37) LMNARORCUSP2ALDH1A1MAPT
SCHEMBL4020347 0.92 KIF11 (0.37) LMNARORCUSP2ALDH1A1MAPT
SCHEMBL4024526 0.92 KIF11 (0.37) LMNARORCUSP2ALDH1A1MAPT
SCHEMBL4028974 0.90 RORC (0.36) LMNARORCUSP2ALDH1A1MAPT
SCHEMBL4028978 0.90 RORC (0.36) LMNARORCUSP2ALDH1A1MAPT
SCHEMBL4776575 0.88 KIF11 (0.39) RORCHDAC4MEN1KMT2AGRIN2B
SCHEMBL4776569 0.88 KIF11 (0.39) RORCHDAC4MEN1KMT2AGRIN2B
SCHEMBL4026439 0.88 TERT (0.40) RORCALDH1A1KCNH2MEN1KMT2A
SCHEMBL4026443 0.88 TERT (0.40) RORCALDH1A1KCNH2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US claimed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US claimed
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 LMNA 315/4885RORC 183/4885USP2 4245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.